Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?
Executive Summary
Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need
You may also be interested in...
Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III
After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.
Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III
After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.
Benlysta May Lead Wave Of New Approvals For Lupus Drugs
The looming approval of Benlysta may create an easier pathway to approval for other lupus candidates, while leaving a potentially broad opportunity for other drugs to fill gaps in its label. Start-Up profiles three emerging lupus drug developers: Azano Pharmaceuticals, Resolve Therapeutics and SuppreMol